Voyageur Pharmaceuticals CEO Brent Willis joined Steve Darling from Proactive to announce the company has received a $600,000 grant from Alberta Innovates, a provincial Crown corporation and Alberta’s largest research and innovation organization. The grant, awarded through the AICE-Market Access Program, is aimed at supporting the commercialization and market access of emerging health technologies in Alberta. Willis shared that the funds will be used for a pivotal study assessing the efficacy of Voyageur’s Frances Creek barium sulfate compared to competing products. The study will focus on evaluating the performance of natural barite from Frances Creek against synthetic barium precipitate and oral iodine products. Currently, synthetic barium and diluted iodine contrast media dominate the fluoroscopy and Computed Tomography examination markets. Voyageur aims to highlight the superior imaging quality of its natural barium sulfate, attributed to its wider particle distribution. This research is expected to enhance the financial viability of the Frances Creek project and strengthen marketing strategies to drive sales growth. Willis also noted that Voyageur is in the testing and refinement phase for its five Health Canada licensed barium contrast products. The company is making steady progress toward its market launch, with a go-to-market plan that includes third-party barium sulfate imports and contract manufacturing partnerships. #proactiveinvestors #voyageurpharmaceuticalsltd #tsxv #vm #vyyrf #ctscan #xray #BrentWillis, #RainCage, #Nanoscience, #MRI, #CTScan, #MedicalBreakthrough, #Fullerenes, #Vanadium, #Gadolinium, #Bismuth, #Iodine, #Radiology, #MedicalInnovation, #DrugDevelopment, #Healthcare, #ScientificBreakthrough